Clinigen launches Japanese business to strengthen Asian presence

Monday, October 24, 2016

Clinigen, a global pharmaceuticals and services group, has launched its Japanese business with the opening of an office in Tokyo, Japan. The establishment of Clinigen K.K. further expands the Group’s presence in Asia, following Clinigen’s acquisition of Link Healthcare in 2015. Alongside the launch, Clinigen K.K. will transfer the Marketing Authorisation for its lead Specialty Pharmaceutical (SP) product Foscavir (foscarnet sodium) back from Nobel Pharma on 1 November 2016. Nobel Pharma has been the distribution partner for Foscavir in Japan since 2011.

[Read More]

Thermo Fisher Scientific opens new clinical services facility in South Korea

Monday, September 12, 2016

To address the growing global demand for clinical services, Thermo Fisher Scientific has announced the official opening of its new state-of-the-art GMP1 standard facility in South Korea. Strategically located in Seoul, the new site will provide local, regional and global pharmaceutical and biotech companies with a one-stop service for clinical supplies—from cGMP storage, local labelling, secondary packaging, comparator sourcing, handling and distribution of ambient and cold chain supplies to clinical site returns management.

[Read More]

The IMS Institute for Healthcare Informatics launches Asia Branch

Wednesday, September 7, 2016

The IMS Institute for Healthcare Informatics has announced the launch of a new branch focused on supporting improved health outcomes across Asia. Based in Singapore, the team will forge relationships in the public and private sectors and apply analytics-driven approaches, based on Real-World Evidence, for disease modeling and insights—providing regional markets with much-needed tools to make better and more cost-effective healthcare policy decisions.

[Read More]

India to revise drugs and cosmetics bill

Tuesday, June 28, 2016

The Union Cabinet, chaired by the Prime Minister Shri Narendra Modi, has decided to withdraw the Drugs and Cosmetics (Amendment) Bill, 2013, which had been introduced in the Rajya Sabha in August of 2013. The Bill had been examined by the Standing Committee of Parliament which had made a number of recommendations for changing the provisions of the Bill. 

[Read More]

Juno, WuXi launch JW Biotechnology in China

Monday, April 11, 2016

Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, and WuXi AppTec, an open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, have started a new company in China. JW Biotechnology (Shanghai) Co., Ltd‘s mission is to build China’s  cell therapy company by leveraging Juno’s world-class chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies together with WuXi AppTec’s R&D and manufacturing platform and local expertise to develop novel cell-based immunotherapies for patients with hematologic and solidorgan cancers. 

[Read More]

Quintiles honored as Best CRO in Asia

Thursday, March 31, 2016

Quintiles has been named the Best CRO in Asia at the 2016 BioPharma Asia Industry Awards, winning the honor for the fourth time in the event’s six-year history. The award goes to the CRO that best demonstrates an ongoing commitment to improving clinical research services in Asia and reducing lead times for customers.

[Read More]

BioPharmaSpec expands into Asia

Thursday, March 24, 2016

BioPharmaSpec, a CRO providing a full range of characterization services for the biotechnology industry, is expanding its business in Asia with business development teams in India and the Asia Pacific region. This will allow scientists in the region to access BioPharmaSpec’s cost-effective, efficient characterization strategies and help accelerate the development of their biosimilars.

[Read More]